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  14 
Abstract 15 
Canine pyometra is a common inflammatory disease of uterus in sexually mature bitches caused 16 
by secondary bacterial infection, leading to change in plasma proteins associated with the innate 17 
immune system. Proteomic investigation is increasingly being applied to canine diseases in order 18 
to identify and quantify significant changes in the plasma proteome. The aim of the study was to 19 
assess and quantify changes in plasma proteome profiles of healthy and pyometra affected bitches 20 
using a TMT-based high-resolution quantitative proteomic approach. As a result, 22 proteins were 21 
significantly down-regulated including transthyretin, antithrombin III, retinol-binding protein, 22 
vitamin D binding protein, paraoxonase 1, and kallikrein, while 16 were significantly up-regulated 23 
including haptoglobin light chain, alpha-1-acid glycoprotein, C-reactive protein precursor, and 24 
lipopolysaccharide-binding protein in dogs with pyometra. Pathway analysis indicated that acute 25 
inflammatory response, regulation of body fluid levels, protein activation cascade, the humoral 26 
immune response, and phagocytosis were affected in pyometra. Validation of biological relevance 27 
of the proteomic study was evident with significant increases in the concentrations of haptoglobin, 28 
C-reactive protein, alpha 1 acid glycoprotein, and ceruloplasmin by immunoassay. Pyometra in 29 
bitches was shown to stimulate an increase in host defense system proteins in response to 30 
inflammatory disease including the acute phase proteins.  31 
Keywords: Canine pyometra, Inflammation, TMT-based proteomics, Acute phase proteins 32 
  33 
Significance 34 
The label-based high-resolution quantitative proteomics analysis and bioinformatic approach used 35 
in this study provide insight into the complex pathophysiology of inflammation associated with 36 
pyometra revealing proteins with biomarker potential. Early diagnosis and therapeutic intervention 37 
may prevent severe complications associated with advancing sepsis in dogs with pyometra. 38 
Therefore the identification of diagnostic biomarkers that, after clinical validation may be used in 39 
veterinary practice and protein relevant to pathways responding to disease are important findings 40 
of the study. Data are available via ProteomeXchange with identifier PXD015951. 41 
Highlights 42 
• Plasma samples from dogs with pyometra were compared to plasma from healthy dogs. 43 
• Quantitative proteomics determined increases in 16 proteins and decreases in 22 proteins 44 
during pyometra.  45 
• Decreases were found in kallikrein, retinol binding protein and transthyretin among others. 46 
• An acute phase protein response was measured by immunoassay in dogs with pyometra 47 
that corresponded to the relevant subset of differntially abundant proteins in the plasma 48 
proteome. 49 
• Increases were measured in haptoglobin, C-reactive protein, alpha 1 acid glycoprotein 50 
and ceruloplasmin. 51 
 52 
Introduction  53 
Canine pyometra is a common inflammatory disease of the uterus in intact, sexually mature 54 
bitches, caused by a secondary bacterial infection [1]. The disease affects on average 25% of all 55 
intact bitches before 10 years of age [2]. Breed strongly influences the risk of developing pyometra, 56 
which indicates that genetic factors may contribute to an increased or decreased susceptibility [3]. 57 
Pyometra is characterized by severe endometrial inflammation and accumulation of pus in the 58 
uterine lumen, with a list of severe subsequent complications reported that includes sepsis, 59 
systemic inflammatory response syndrome (SIRS), septic shock, peritonitis, disseminated bacterial 60 
infection and multi‐organ dysfunction [1, 3]. Therefore, early identification of the disease and 61 
appropriate treatment is crucial to obtain a favourable outcome and increase chances of survival 62 
of this life threatening condition. 63 
The diagnosis is based on case history, physical examination, and laboratory analyses, often 64 
combined with radiography and/or ultrasonography of the uterus and ovaries. Clinical signs vary 65 
depending on the severity of the disease. Leukocytosis, neutrophilia with left shift, anaemia, 66 
monocytosis, hypoalbuminemia as well as affected liver or kidney function are common findings 67 
[3, 4]. Surgical ovariohysterectomy is the safest and most effective treatment for pyometra, but 68 
new protocols for improved medical treatment alternatives have also been tested with promising 69 
results [3].  70 
In recent years, new omics technologies have been developed, which has prompted possibilities 71 
for novel studies. In this respect, veterinary proteomics is an evolving field which holds a great 72 
promise not only for fundamental and applied discoveries regarding pathophysiological 73 
mechanisms of animal species diseases, but can also be implemented in comparative applications 74 
of relevance to human diseases research [5]. Furthermore, the application of proteomics to the 75 
study of canine disease for pathophysiological and biomarker analysis has been accelerating [6-9].  76 
As a common and well described naturally occurring inflammatory disease, canine pyometra 77 
represents a good model to study the inflammatory response. The inflammatory response is an 78 
intricate cross-talk between cytokines, acute phase proteins (APPs) and cells [10, 11], but many of 79 
these ongoing interactions remain unclear, while its exacerbation is associated with high mortality 80 
in human and veterinary medicine. Therefore, an insight into proteomic profile of plasma in dogs 81 
with pyometra may provide important findings into general mechanisms operating during diverse 82 
inflammatory reactions. 83 
The aim of this study was to identify and quantify differentially abundant proteins (DAP) in plasma 84 
of bitches with pyometra compared to plasma from healthy dogs. This aim was achieved by an 85 
isobaric tandem mass tag (TMT) label-based high-resolution quantitative proteomic approach. A 86 
subsequent aim was to confirm changes in the DAP found by proteomics by using immunoassay 87 
to measure plasma concentrations of the canine plasma protein haptoglobin (Hp), C-reactive 88 
protein (CRP), 1 acid glycoprotein (AGP) and ceruloplasmin (CP). Furthermore functional 89 
bioinformatic analysis was employed for elucidating molecular mechanisms and pathways 90 
associated with canine pyometra.  91 
 92 
2. Materials and methods 93 
2.1 Animals and sample collection 94 
Six clinically healthy dogs (control group) and 6 dogs with pyometra were enrolled in the study. 95 
All dogs were admitted to the Small Animal Clinic, University of Veterinary Medicine Hannover 96 
and treated in accordance with the German Animal Welfare Law.  97 
The experimental design was approved by the Animal Welfare Officer of the University of 98 
Veterinary Medicine and by the Ethic Committee of the responsible authority (Lower Saxony State 99 
Office for Consumer Protection and Food Safety, reference number 17A 101). Healthy dogs for 100 
blood collection were recruited by launching a call in the University of Veterinary Medicine 101 
Hannover network for students and staff members for haemostasis study, providing a free clinical 102 
and laboratory health check of their animal in combination with the blood collection. Residual 103 
sample material was used in the present study. Only animals for which the clinical examination, a 104 
complete haematology profile and clinical chemical profile (including liver enzymes, bilirubin, 105 
urea, creatinine, cholesterol, glucose, total protein, albumin and calcium) were unremarkable, i.e. 106 
did not reveal any deviations from the reference intervals, were included in the study. Healthy dogs 107 
had a median age of 5 years (range 5 months–8 years), 4 were females and 2 males (1 castrated). 108 
Different breeds were represented (3 mixed-breed, 1 Golden Retriever, 1 Labrador, 1 Hovawart). 109 
Before taking the blood samples, all dogs were fasted for at least 12 hours with free access to 110 
water.  111 
Blood samples from dogs with pyometra were collected at the time of initial presentation to the 112 
Small Animal Clinic for diagnostic purposes and the residual sample material was used for the 113 
present project. Diagnosis was based on clinical, ultrasonographic and laboratory findings as well 114 
as findings during laparotomy (all dogs received an ovariohysterectomy) and partly confirmed by 115 
histopathology. Five of 6 dogs had leukocytosis and 3 had increased body temperature, thereby, 3 116 
fulfilled criteria of a systemic inflammatory response syndrome. Dogs with pyometra had a median 117 
age of 10 years (range 5–11 years). Different breeds were represented (2 Golden Retrievers, 118 
Labrador, Newfoundland, Siberian Husky, and a mixed-breed dog).  119 
Plasma was obtained by centrifugation of blood collected in lithium-heparin tubes. Aliquoted 120 
samples were stored at −80 °C until analysed. All samples used for repetitive analysis were frozen 121 
in aliquots and only vials needed for each assay run were used, to avoid the repetitive thawing and 122 
freezing effect. 123 
2.2 Proteomic analysis by LC-MS/MS 124 
Proteomic analysis of canine plasma samples was performed by TMT-based quantitative approach 125 
as described previously [12]. In brief, after total protein concentration determination using a BCA 126 
assay (Thermo Scientific, Rockford, USA), 35 μg of total proteins from samples and internal 127 
standard (a pool of equal protein amount from all samples as a reference for normalization) were 128 
diluted to a volume of 50 μL using 0.1 M triethyl ammonium bicarbonate (TEAB, Thermo 129 
Scientific, Rockford, USA), reduced by adding 2.5 μL of 200 mM dithiothreitol (60 min, 55 °C) 130 
(DTT, Sigma Aldrich, St. Louis, MO, USA), alkylated by adding 2.5 μL of 375 mM iodoacetamide 131 
(30 min, room temperature in the dark) (IAA, Sigma Aldrich, St. Lois, MO, USA) and acetone-132 
precipitated (300 μL, overnight, −20 °C). Protein pellets were collected subsequently by 133 
centrifugation (9000 × g, 4 °C), dissolved in 50 μL of 0.1 M TEAB and digested using 1 μL of 134 
trypsin (1 mg/mL, Promega; trypsin-to-protein ratio 1:35, at 37 °C overnight). 135 
TMT sixplex reagents (Thermo Scientific, Rockford, IL, USA) were prepared according to the 136 
manufacturer's procedure and 19 μL of the appropriate TMT label was added to each sample for 137 
the labelling reaction (60 min, room temperature) which was quenched by 5% hydroxylamine 138 
(Sigma-Aldrich, St. Louis, MO, USA). Five TMT-modified peptide samples were combined with 139 
the internal standard (labelled with TMT m/z 126) into the new tube, aliquoted, dried and stored at 140 
−20 °C for further analysis.  141 
High resolution LC-MS/MS analysis of TMT-labelled peptides was carried out using an Ultimate 142 
3000 RSLCnano system (Dionex, Germering, Germany) coupled to a Q Exactive Plus mass 143 
spectrometer (Thermo Fisher Scientific, Bremen, Germany). Peptides were dissolved in loading 144 
solvent (1% ACN, 0.1% formic acid) and desalted on the trap column (C18 PepMap100, 5 μm, 145 
100A, 300 μm×5 mm) for 12 min at the flow rate of 15 μL/min and separated on the analytical 146 
column (PepMap™ RSLC C18, 50 cm×75 μm) using a linear gradient of 5–45% mobile phase B 147 
(0.1% formic acid in 80% ACN) over 120 min at the flow rate of 300 nL/min. Mobile phase A 148 
consisted of 0.1% formic acid in water. Eluent was ionised using a 10 μm-inner diameter SilicaTip 149 
emitter (New Objective, USA) mounted within nanospray Flex ion source (Thermo Fisher 150 
Scientific, Bremen, Germany). Data dependent acquisition in positive ion mode was performed 151 
using a DDA Top8 method. Full scan MS spectra were acquired in range from m/z 350.0 to m/z 152 
1800.0 with a resolution of 70000, 110 ms injection time, AGC target 1×106, a ± 2.0 Da isolation 153 
window and the dynamic exclusion 30 s. HCD fragmentation was performed at step collision 154 
energy (29% and 35% NCE) with a resolution of 17500 and AGC target of 2×105. Precursor ions 155 
with unassigned charge state, as well as charge states of +1 and more than +7 were excluded from 156 
fragmentation. 157 
Acquired MS/MS spectra were analysed for protein identification and quantification using the 158 
SEQUEST algorithm implemented into Proteome Discoverer (version 2.0., ThermoFisher 159 
Scientific). Database search against Canis lupus FASTA files (downloaded from NCBI database 160 
13/10/2016, 41787 entries) was performed according to the following parameters: two trypsin 161 
missed cleavage sites, precursor and fragment mass tolerances of 10 ppm and 0.02 Da, 162 
respectively; carbamidomethyl (C) fixed peptide modification, oxidation (M), deamidation (N,Q) 163 
and TMT sixplex (K, peptide N-terminus) dynamic modifications. The false discovery rate (FDR) 164 
for peptide identification was calculated using the Percolator algorithm in the Proteome Discoverer 165 
workflow. At least two unique peptides and 5% FDR were required for reporting confidently 166 
identified proteins.  167 
Protein relative quantification was accomplished by correlating the relative intensities of reporter 168 
ions extracted from tandem mass spectra to that of the peptides selected for MS/MS fragmentation. 169 
The internal standard was used to combine the results for each protein within the TMT experiments 170 
(sixplexes). The mass spectrometry-based proteomics data have been deposited to the 171 
ProteomeXchange Consortium via the PRIDE [13] partner repository with the dataset identifier 172 
PXD015951. 173 
2.3 Statistical analysis 174 
Protein expression from pyometra and control group as determined by TMT proteomics were 175 
compared using the non-parametric Wilcoxon test, after an outlier correction by a Dixon test in 176 
each group. Proteins with a p-value < 0.05 were considered as significantly different between 177 
disease and control groups. For each protein, fold changes have been calculated as follow: -log2 178 
(meandisease/mean control). Statistics have been performed using RStudio v1.1.463 and the script 179 
dedicated to LC-MS data analysis. R packages used for statistics were readr, outliers, data.table, 180 
plotly, and xlsx [14]. Statistical analysis for immunoassay results were performed using EZR 1.37 181 
[15] which is a graphical interface for R commander [14]. The Pearson correlation coefficient was 182 
used to compare immunoassays results with protein abundance in proteomics (fold change) and 183 
the nonparametric Mann-Whitney test was used to assess differences between pyometra and 184 
control groups determined by immunoassay, with p < 0.05 considered as statistically significant. 185 
2.4 Bioinformatic analysis 186 
The list of significant proteins has been converted to a list of Gene symbols through BioDBnet 187 
(https://biodbnet-abcc.ncifcrf.gov). Then, genes from Canis lupus familiaris have been converted 188 
to their orthologous genes in Homo sapiens by the tool Biomart from Ensembl 189 
(www.ensembl.org). Using the Cytoscape (v3.6.1) application CluePedia (1.5.2), original list of 190 
significant genes have been enriched with their best interactors according to IntAct and Reactome 191 
databases (maximum 5 added interaction per gene). Then all genes (original and enriched) were 192 
submitted to a Gene Ontology (GO) analysis using the Cytoscape application ClueGO (v2.5.2) 193 
with following parameters: GO_BiologicalProcess in Homo sapiens, evidence codes used = 194 
All_without_IEA, GO level from 3 to 12, Kappa score threshold = 0.4, correction method = 195 
Bonferroni step down. 196 
Generated GO terms were submitted to a refinement step by Revigo (revigo.irb.hr) to remove 197 
redundant terms, define groups of GO terms and assign a term as leading GO. All this 198 
bioinformatics analysis was represented using Cytoscape with a radial layout. Fold changes data 199 
for original nodes were included as a color gradient.  200 
2.5 APPs measurements 201 
APPs concentrations were determined using SPARCL immunoassays. SPARCL™ (Spatial 202 
Proximity Analyte Reagent Capture Luminescence) novel technology is a proximity-dependent, 203 
homogenous, chemiluminescent detection method [16] that allows rapid and cost effective 204 
immunoassay development, validation and sample analysis (Lumigen Inc, Michigan, USA). 205 
Canine specific SPARCL assays were used for Hp, CRP, AGP and CP. (Life Diagnostics Inc., 206 
West Chester, USA). Validation of SPARCL immunoassays was performed to assess the assays’ 207 
precision, accuracy, detection limit and specificity. The precision was determined as the mean 208 
coefficient of variance (CV) with triplicate assay for four samples (n=12) with varying 209 
concentrations of the DAP repeated in a single assay for intra-assay and over repeated assays for 210 
inter-assay CV. The accuracy was determined by parallel dilution of samples with high 211 
concentrations of the DAP as the mean (+SD) of the observed divided by the expected 212 
concentration expressed as a percentage. The minimal detected concentration of the assays was 213 
determined as the lowest concentration of purified protein that could be measured in sample with 214 
minimal dilution and in plasma after adjustment for that dilution. Specificity was dependent on the 215 
nature of the antigen used to produce the antibody utilised in the assays. Nonparametric Mann-216 
Whitney test was used to assess differences between pyometra and control group, with p < 0.05 217 
considered as statistically significant.   218 
 219 
3. Results 220 
3.1 Proteomics 221 
In this study, the label-based proteomic approach enabled the identification of 210 quantifiable 222 
proteins according to set criteria (2 unique peptides and 5% FDR). In total, there were 38 proteins 223 
with significantly different abundances following FDR correction, between healthy dogs and those 224 
with pyometra, 22 of them were down-regulated and 16 up-regulated in diseased dogs (Table 1).  225 
Outlier correction reduced the numbers per group for the statistical analysis of proteomic results 226 
but for the subset selected for validation of the proteomic results (Section 3.3) no samples were 227 
excluded (n=6 in all groups). 228 
A volcano plot of fold changes (x-axis) and their associated -log10 transformed p-values (y-axis) 229 
for the proteins identified by LC-MS is given in Figure 1. 230 
3.2 Bioinformatics 231 
The list of final GO terms that were represented with their respective number of genes (original 232 
and enriched) inside each term and their associated p-value (expressed as -log10), is given in Table 233 
2 and illustrated by histogram (Figure 2). 234 
The gene ontology (GO) terms represented for pyometra, filtered by REVIGO and presented by 235 
Cytoscape with a radial layout are given in Figure 3A with the full interaction (detailed view can 236 
be found in Supplementary Information) and Figure 3B where the interactions at nodes in 237 
regulation of body fluid levels; protein activation cascade; humoral immune response; acute 238 
inflammatory response as best interacting GO terms are evident. Fold changes data for original 239 
nodes are presented as a color gradient.  240 
3.3 Acute Phase Protein measurements in the validation of proteomics results 241 
The SPARCL immunoassays used for validation of the proteomic results for DAP were themselves 242 
validated (Table 3) with intra-assay CVs ranging from 1.4% to 6.5% and inter-assay CVs ranging 243 
from 1.7% to 13.3%. The parallel dilution assessment for accuracy was between 96% to 102% for 244 
the four proteins. The minimal detected amount for the DAP ranged from 3.6 ng/ml for CRP to 50 245 
ng/ml for α1 acid glycoprotein. The specificity of the SPARCL immunoassays depends on the 246 
nature of the antigen for antibody production, which was the native canine protein for Hp, CRP, 247 
AGP and CP. All SPARCL immunoassays assays were valid for use in comparison of the 248 
quantitative TMT proteomic results to their plasma concentrations. 249 
Results of APPs measurements are presented in Table 4, as median and interquartile range, with 250 
corresponding p-value. All measured APPs were significantly different between pyometra and 251 
control groups. Higher plasma concentrations of APPs were found in samples from the pyometra 252 
group for Hp, CRP, AGP and CP. 253 
The APPs measurements determined by SPARCL assays were compared to the fold change as 254 
determined by proteomic analysis of the same samples, thus providing validation of the proteomics 255 
results. Both the TMT-based quantitative proteomic approach and the SPARCL immunoassays 256 
showed independently that in pyometra the concentration of Hp, CRP, AGP and CP were higher 257 
than in healthy dogs (Fig 4 a-d). There was significant association between the immunoassay and 258 
quantitative proteomic results demonstrated by the correlations with r > 0.85, and p < 0.001 in all 259 
correlations, as presented in Figures 5 a-d. 260 
4 Discussion  261 
The inflammatory and coagulation changes that accompany severe infections in dogs are similar 262 
to those observed in humans, which is why spontaneous sepsis in dogs may serve as a 263 
physiologically relevant disease model for human sepsis [17]. Pyometra is a common bacterial 264 
infection of the uterus in dogs that frequently progresses into SIRS and sepsis [18, 19]. Recently, 265 
the inflammatory response during pyometra has been more closely explored, and reported uterine 266 
gene microarray expression pattern showed that up- and down-regulated genes in pyometra are 267 
associated with chemokines, cytokines, inflammatory cell extravasation, anti‐bacterial action, the 268 
complement system and innate immune responses [20]. Using the high resolution label-based 269 
relative quantification proteomic approach, we have found 38 differentially abundant plasma 270 
proteins between dogs with pyometra and healthy dogs. Based on bioinformatic analyses, 271 
identified differences indicate involvement of several pathways in this disease, including the acute 272 
inflammatory response, regulation of body fluid levels, protein activation cascade, the humoral 273 
immune response and phagocytosis. 274 
The acute phase response (APR) is a nonspecific, immediate and complex inflammatory reaction 275 
of the host that occurs shortly after any tissue injury (caused by infection, inflammation, neoplasia, 276 
trauma or other causes). During the APR, pro-inflammatory cytokines stimulate the production of 277 
positive APPs in hepatocytes leading to increase in their plasma concentration, while negative 278 
APPs decrease in concentration [10]. Most of the proteins found as significantly different abundant 279 
proteins between the pyometra and control groups are known to be APPs, such as CRP, Hp, CP, 280 
AGP, transthyretin, paraoxonase-1 (PON-1), inter-alpha-trypsin inhibitor heavy chain H1, alpha-281 
2-HS-glycoprotein and transferrin. These findings confirm activation of the APR in canine 282 
pyometra. As APPs levels during the course of inflammation in an organism reflect the state of the 283 
innate immune system activation, and for confirmation of the biological validation of the 284 
investigation, the panel of canine APPs proteins, Hp, CRP, AGP and CP were quantified by 285 
immunoassays. These demonstrated equivalent responses to the proteomic analysis thus validating 286 
the proteomic approach and also extended previous assessment of APR in pyometra. 287 
Previous studies found higher plasma concentrations of CRP, Hp and AGP, as well as SAA in 288 
bitches with pyometra compared to plasma of healthy dogs [21-24]. CRP level, together with the 289 
percentage of band neutrophils, has been proposed as laboratory marker in order to differentiate 290 
pyometra and cystic endometrial hyperplasia/mucometra [25]. CRP is a well known major positive 291 
APP in both humans and dogs, used as sensitive, but nonspecific biomarker of systemic 292 
inflammation [11]. This study identified and quantified CP by proteomics and immunoassay as 293 
another positive APP which has an important role in protecting host tissues from toxic oxygen 294 
metabolites released from phagocytic cells during inflammatory states, and copper transport and 295 
antioxidant defence. Ceruloplasmin is a known APP in dogs, with higher and earlier increase in 296 
concentration during inflammation than in humans [10, 26].  297 
Except those APPs, other proteins were shown by the proteomics investigation to have significant 298 
fold change in the pyometra group compared to the healthy group. α2-Heremans–Schmid-(α2-HS) 299 
glycoprotein (A2HSG) is a plasma protein synthesized in liver and is a homologue of bovine 300 
fetuin-A. This protein is a negative APP whereas its level declines following infection, 301 
inflammation and malignancy and here had a negative fold change of -0.55. α2-HS glycoprotein 302 
has also been identified as a negative APP in chicken plasma following experimental induction of 303 
the inflammatory response to bacterial lipopolysaccharide endotoxin [12]. 304 
Four identified proteins involved in haemoglobin and iron metabolism and transport are Hp, 305 
hemopexin with increased abundance, serotransferrin and transferrin receptor protein 1 (TfR1) 306 
with lower abundance in pyometra. The scavenger protein hemopexin, which bind extracellular 307 
heme, provides the second line of defence preventing haemoglobin-mediated oxidative damage 308 
during the intravascular haemolysis and heme-bound iron loss [27]. While hemopexin helps in 309 
scavenging free heme, the free iron is taken up and transported by serotransferrin, a negative APP 310 
found in this study. Transferrin receptor protein 1 is a membrane glycoprotein which has a role in 311 
transport of iron from plasma to cell and whose expression on the surface of cells is dependent on 312 
tissue iron status. Levels of TfR1 are used as biomarker in iron deficiency and anaemia of chronic 313 
disease in humans [28].  314 
Transthyretin (also known as prealbumin) is an important transport protein, which plays an 315 
essential role in the binding of thyroid hormones and vitamin A, the latter through interaction with 316 
retinol binding protein. Lower protein abundance found in pyometra group confirmed both 317 
transthyretin and retinol binding protein as negative APP in dogs, due to decreased synthesis in 318 
inflammation, trauma, tissue injury or stress [29].  319 
Paraoxonase 1 (PON1) is considered as a marker of diseases involving oxidative stress, 320 
inflammation and liver disease. PON1 is a negative APP bound to high density lipoproteins (HDL) 321 
and during the APR protects HDL from peroxidation. During inflammation HDL molecules lose 322 
apolipoprotein A1, esterified cholesterol, and most of the HDL-associated enzymes, including 323 
PON1, which is replaced mainly by serum amyloid A and ceruloplasmin [30]. Decrease of PON1 324 
has been demonstrated in dogs with acute pancreatitis, leishmaniosis and babesiosis [31-33]. It is 325 
a limitation of the study that analysis of PON1, as an example of a negative acute phase reactant 326 
was not available at the time of investigation and its assay in samples from bitches with pyometra 327 
should be considered in the future. 328 
One of the findings in the complex pathophysiology of inflammation is evidence of excess 329 
systemic protease activity. An array of endogenous protease inhibitors have evolved whose 330 
function is to prevent excess activation of proteases and limit the potential injurious actions of 331 
protease activation on endothelial and epithelial tissues [34]. Many of protease inhibitors, such as 332 
antithrombin, alpha-1 antitrypsin, and alpha-2-antiplasmin were detected by proteomic analysis in 333 
this study. They are rapidly consumed in sepsis, often leading to a failure to appropriately regulate 334 
protease activity. 335 
The inter-alpha-trypsin inhibitors (ITI) are a family of plasma serine protease inhibitors, composed 336 
of a light chain – bikunin, and five homologous heavy chains, contributing to extracellular matrix 337 
stability by covalent linkage to hyaluronan playing a role in inflammation and carcinogenesis in 338 
humans [35]. In  inflammationinter-alpha-trypsin inhibitors heavy chain (ITIH) family members 339 
have been demonstrated to be both positive and negative APPs under various conditions. In our 340 
study, lower protein abundances were found for both, ITIH1 and ITIH2, in the pyometra group 341 
compared to controls. Rapid depletion of ITIH levels may contribute to uncontrolled proteolytic 342 
activity in the plasma and exacerbate the systemic inflammatory response in severe sepsis. The 343 
reduced ITIH1 and ITIH2 levels in the plasma may contribute to reduced protease inhibitor activity 344 
and excess protease-mediated tissue injury in pyometra group. 345 
Coagulation pathways were shown to be affected in pyometra by the proteomics study. 346 
Antithrombin III, as part of the most important anticoagulant pathway, inhibits fibrinogen 347 
conversion into plasmin by creating thrombin-antithrombin (TAT) complexes. Antithrombin III 348 
activity was decreased in bitches with endometritis-pyometra complex due to excessive 349 
mobilisation and in response to high levels of IL-6, which accompany various inflammations [36]. 350 
A lower protein abundance of antithrombin III was found in the pyometra group, possibly due to 351 
increased consumption as a result of ongoing thrombin generation and proteolytic degradation by 352 
elastase from activated neutrophils. 353 
Alpha-2-antiplasmin, which was reduced in the pyometra group, is a major inhibitor and regulator 354 
of fibrinolysis and one of the essential factors involved in haemostasis. It is a member of the serine 355 
proteinase inhibitor (serpin) family and inhibits proteases in general, including trypsin, 356 
chymotrypsin, plasma kallikrein, but its main physiological activity is very rapid inhibition of 357 
plasmin by forming a stable complex with this proteinase [37] and its reduction may suggest 358 
consumption of fibrinolysis inhibitors and increased fibrinolytic activity due to hypercoagulable 359 
state present in inflammation. Excess free plasmin is bound by α2-macroglobulin, a relatively 360 
nonspecific inhibitor of fibrinolysis, and this protein was increased in the pyometra group 361 
accordingly. 362 
Two actin-scavenging proteins, vitamin D binding protein, also known as group-specific 363 
component globulin (Gc-globulin), and gelsolin, had lower protein abundances in pyometra group 364 
compared to controls. Vitamin D binding protein binds to monomeric G-actin, which is released 365 
by the action of gelsolin. During the scavenging process, both G-actin–gelsolin and G-actin–366 
vitamin D binding protein complexes are formed and subsequently cleared by the 367 
reticuloendothelial system, resulting in consumption of both gelsolin and vitamin D binding 368 
protein [38]. To date, vitamin D binding protein has been recognized widely as a protein with 369 
markedly decreased concentrations in inflammatory and necrotic diseases. The extent of the 370 
decrease may have prognostic significance for patient outcomes.  371 
The analysis of interaction biological processes by GO terms has identified the processes most 372 
affected by pyometra revealing that the regulation of body fluid levels, the protein activation 373 
cascade relating to coagulation of blood proteins, humoral immune response and the acute 374 
inflammatory response were the most affected. In this representation of the pathways responding 375 
to the disease, the APPs appear at locations related to their biological activities rather than as part 376 
of an acute phase protein response. Thus CRP is primarily linked to the phagocytosis node, 377 
haptoglobin to the nodes of response to reactive oxygen species, hydrogen peroxide catabolic 378 
process and cofactor catabolic process and AGP (gene ORM1) and lipopolysaccharide binding 379 
protein to the acute inflammatory response node. Notable among the nodes with less interaction 380 
was the retinoid metabolic process, response to reactive oxygen species, the cellular iron ion 381 
homeostasis and cholesterol transport, highlighting that these metabolic processes may have 382 
consequences for the development of pyometra and should not be overlooked in understanding the 383 
pathophysiology of this disease. 384 
A limitation of this study is that the control group was substantially younger than the patients, i.e. 385 
not age-matched. Although, age-dependent changes of the vessel wall and/or subclinical multi- 386 
morbidity in elderly dogs may result in increasing concentrations of inflammatory reaction 387 
proteins and coagulation factors, those age-dependent changes in adult healthy dogs are actually 388 
only minimal [39, 40]. In addition, the food intake in the patient group is not exactly defined in 389 
contrast to the control group, but it can be assumed that the patients had a similarly empty stomach, 390 
because the pyometra disease is usually associated with inappetence (and food is withdrawn after 391 
hospitalization before surgery).   392 
5 Conclusion 393 
Label-based high-resolution quantitative proteomics analysis and bioinformatic approach used in 394 
this study has identified numerous DAP that are either increased or decreased in the plasma of 395 
bitches during pyometra unlike previously reported studies addressing pyometra being focused 396 
exclusively on several plasma proteins. These changes in DAP represent a valuable tool for 397 
elucidating the complex pathophysiology of inflammation associated with pyometra and unveiling 398 
disease relevant proteins with biomarker potential. Further quantification by immunoassay of a 399 
subset of the DAP comprising HP, CRP, AGP and CP not only provide evidence of the stimulation 400 
of the APP response during pyometra but also validation of the proteomic results.  Early diagnosis 401 
and therapeutic intervention may prevent severe complications associated with sepsis in dogs with 402 
pyometra and it is crucial to identify diagnostic or prognostic biomarkers such as the APP, that 403 
can be used in veterinary practice. APPs play an important role in modulating the inflammatory 404 
immunological response, and their blood concentrations reflect the intensity of inflammation, 405 
which makes APP determination of diagnostic and prognostic value in pyometra. Determination 406 
of haemostatic profile is also of importance in pyometra, in order to timely address haemostatic 407 
function impairment. 408 
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  533 
Table 1: Proteins showing significant differences in abundance between plasma from dogs with 534 
pyometra and healthy dogs. 535 








258498 haptoglobin light chain, HpL 
chain [dogs, Peptide, 83 aa] 
0.035 2.19 42.17 3 
73957095 haptoglobin-like 0.035 1.83 70.89 24 
123511 RecName: Full=Haptoglobin 0.035 1.83 74.77 24 
258499 haptoglobin heavy chain, HpH 
chain [dogs, Peptide, 245 aa] 
0.035 1.80 82.86 20 
345777714 alpha-1-acid glycoprotein 1 0.033 1.26 42.93 9 
936976329 C-reactive protein precursor 0.033 1.23 38.12 5 
345789637 lipopolysaccharide-binding 
protein 
0.033 1.16 28.27 11 
16607721 interleukin-13 receptor subunit 
alpha-2 precursor 
0.033 0.87 31.44 10 
17066528 immunoglobulin gamma 
heavy chain C 
0.033 0.81 45.78 11 
345792424 alpha-2-macroglobulin 0.035 0.54 56.34 59 
545504250* C4b-binding protein alpha 
chain 
0.035 0.42 47.69 23 
73988725 hemopexin 0.035 0.29 56.55 17 
73990367 ceruloplasmin isoform X2 0.035 0.28 37.18 28 
545539301 ceruloplasmin isoform X1 0.035 0.28 36.20 28 
45826457*** ceruloplasmin, partial 0.046 0.28 89.04 5 
928179401** vitamin K-dependent protein S 0.046 0.24 16.20 13 
73985485 inter-alpha-trypsin inhibitor 
heavy chain H1 isoform X1 
0.035 -0.32 30.11 22 
73967363 alpha-2-antiplasmin isoform 
X2 
0.033 -0.32 20.16 8 
545512145 alpha-2-antiplasmin isoform 
X1 
0.033 -0.32 17.84 8 
57090343 plasma serine protease 
inhibitor 
0.046 -0.34 22.11 7 
545533419 inter-alpha-trypsin inhibitor 
heavy chain H1 isoform X2 
0.035 -0.34 25.79 18 
345777712 protein AMBP 0.035 -0.35 26.65 8 
73975797 serum 
paraoxonase/arylesterase 1 
0.046 -0.36 26.20 8 
73949158 inter-alpha-trypsin inhibitor 
heavy chain H2 
0.035 -0.38 27.80 20 
359320010 antithrombin-III 0.033 -0.46 47.96 19 
928167632 serotransferrin 0.035 -0.47 80.71 56 
399567834* hemoglobin subunit beta-like 0.046 -0.53 80.95 11 
10946310 transferrin receptor 0.033 -0.53 12.73 10 
545552733 transferrin receptor protein 1 
isoform X1 
0.033 -0.53 12.73 10 
545521763 vitamin D-binding protein 0.033 -0.54 73.84 25 
227343817* Chain B, Crystal Structure Of 
Dog (Canis Familiaris) 
Hemoglobin 
0.046 -0.54 86.99 12 
545553759 alpha-2-HS-glycoprotein 0.035 -0.55 37.53 9 
545518174 gelsolin 0.033 -0.57 26.59 17 
57089193 transthyretin 0.033 -0.58 46.94 6 
208342090** immunoglobulin heavy chain 
variable region, partial 
0.046 -0.59 21.28 2 
928175781 retinol-binding protein 4 0.035 -0.69 50.75 7 
545553762 histidine-rich glycoprotein 
isoform X1 
0.046 -0.71 20.36 10 
337298514*** plasma kallikrein 0.046 -0.72 7.39 3 
aAccession number from NCBI protein database for Canis lupus familiaris 536 
bFold changes calculated as: -log2 (meandisease/mean control) 537 
The group size of the healthy dogs and those with pyometra was n=6 for all proteins listed except 538 
for proteins where outlier exclusion reduced the number per group and are labelled * where the 539 
healthy group n=5 and pyometra n=6; ** where the healthy group n=6 and pyometra n=5; *** 540 
where the healthy group n=5 and pyometra n=5 541 
  542 
Table 2. Five best interacting Gene Ontology (GO) leader terms and number of genes associated 543 
in this study for pyometra retained by REVIGO 544 
 545 
GOTerm Number of associated 
genes 
- log10 p-value 
regulation of body fluid levels 45 23.025 
protein activation cascade 40 31.910 
humoral immune response 35 16.967 
acute inflammatory response 32 23.122 




Table 3  Validation of the immunoassays used for assessment of a subset of the differntially abundant proteins in plasma of dogs with 549 
pyometra.  550 
 551 
Protein    
Precision Accuracy: 
parallel dilutions  
















Antigen used for antibody production 
        
Haptoglobin 5.5 6.9 96+4 1.7 34   1:20  Purified native canine haptoglobin 
C-Reactive protein 5.4 13.3 99+4 0.18 3.6   1:20  Purified native canine C-reactive protein 
α1 acid glycoprotein 1.4 1.7 101+5 2.5 50   1:20  Purified native canine α1 acid glycoprotein 
Ceruloplasmin 5.8 17 102+5 0.34 6.8   1:20  Purified native canine ceruloplasmin 
        
 552 
 553 
Table 4: Median and interquartile range of acute phase proteins in the healthy control group of 554 
dogs and in the group of dogs with pyometra. 555 
Parameter 
(unit) 
Control group   
(N = 6) 
Pyometra group 
(N = 6) 
P value  
Hp (mg/ml) 0 (0 – 0.34) 6.81 (2.39 - 10.48) 0.002 
CRP (g/ml) 1.23 (0 – 5.66) 466 (386.1 - 488) 0.002 
AGP (g/ml) 151.9 (117.1 – 249) 1663 (819 – 2568) 0.002 
CP (g/ml) 139 (125.8 – 182.4) 248.3 (216 – 280.7) 0.009 
 556 
 557 
  558 
 559 
Legend to Figures  560 
Figure 1. Volcano plot for plasma from dogs with pyometra vs plasma from healthy dogs (control 561 
group). Volcano plot of fold changes (x-axis) and their associated log10 transformed p-values (y-562 
axis) for the proteins identified by LC-MS. Proteins with significant different abundance between 563 
pyometra and control groups (-log10 p > 1.3) are in green, non-significant proteins (-log10 p < 564 
1.3) are in red. 565 
Figure 2: The final GO terms that were represented by the plasma protein changes occurring in 566 
canine pyometra. 567 
Figure 3. Gene ontology (GO) terms represented for pyometra, filtered by REVIGO and detected 568 
by Cytoscape, (A) complete pathway interactions available in supplementary data for examination 569 
of detail; (B) enlargement of pathway interactions to show links between proteins showing change 570 
in quantitative proteomics and GO nodes in regulation of body fluid levels; protein activation 571 
cascade; humoral immune response; acute inflammatory response.  Blue diamond is not detected 572 
protein; red diamond is detected protein, red diamond green fill is a protein increased in pyometra; 573 
red diamond with red fill is a protein decreased in pyometra. Minutely detailed view is available 574 
in Supplementary data.  575 
Figure 4. Comparison of APPs measurements by SPARCL (g/mL or mg/mL) and by TMT label-576 
based quantitative proteomics (fold change): a) haptoglobin; b) C-reactive protein; c) alpha-1-acid 577 
glycoprotein; d) ceruloplasmin. Difference between healthy and pyometra groups was analysed by 578 
Mann Whitney U Test and with n=6 in all groups. 579 
Figure 5. Correlation of APPs measurements by SPARCL (g/mL or mg/mL) and by TMT 580 
label-based quantitative proteomics (fold change): a) Haptoglobin (R = 0.992; p=3.25e-10),  b) 581 
C-reactive protein (R = 0.996; p=3.27e-7); c) Alpha-1-acid glycoprotein (R = 0.95; p = 2.21e-6); 582 
d) Ceruloplasmin (R = 0:857; p= 0.000371)  583 
 584 
Figure 1. 585 
 586 
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